Chemotherapy confers a conserved secondary tolerance to EGFR inhibition via AXL-mediated signaling bypass.

Sci Rep · 2021 · PMC8044124 · PMID 33850249

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

considerably significantno p-value reported

We also showed that there is a considerably significant co-resistance trajectory to the EGFR-TKI gefitinib in cell lines classified as resistant to 11 cytoskeleton-targeting antimitotic drugs (CTDs), representing a sub-class of AMDs.

also in 280 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.